- home
- Advanced Search
- COVID-19
- Publications
- EU
- The Journal of Infectious Diseases
- COVID-19
- Publications
- EU
- The Journal of Infectious Diseases
Loading
description Publicationkeyboard_double_arrow_right Article 2023Publisher:Oxford University Press (OUP) Funded by:EC | ERVEEC| ERVEYoussif M Ali; George W Carnell; Stefano Fumagalli; Domenico Mercurio; Serena Seminara; Nicholas J Lynch; Priyanka Khatri; Chanuka H Arachchilage; Luca Mascheroni; Clemens Kaminski; Charlotte L George; Hazel Stewart; Munehisa Yabuki; Gregory Demopulos; Jonathan L Heeney; Wilhelm Schwaeble;pmid: 37878754
Abstract Most patients with COVID-19 in the intensive care unit develop an acute respiratory distress syndrome characterized by severe hypoxemia, decreased lung compliance, and high vascular permeability. Activation of the complement system is a hallmark of moderate and severe COVID-19, with abundant deposition of complement proteins in inflamed tissue and on the endothelium during COVID-19. Using a transgenic mouse model of SARS-CoV-2 infection, we assessed the therapeutic utility of an inhibitory antibody (HG4) targeting MASP-2, a key enzyme in the lectin pathway. Treatment of infected mice with HG4 reduced the disease severity score and improved survival vs mice that received an isotype control antibody. Administration of HG4 significantly reduced the lung injury score, including alveolar inflammatory cell infiltration, alveolar edema, and alveolar hemorrhage. The ameliorating effect of MASP-2 inhibition on the severity of COVID-19 pathology is reflected by a significant reduction in the proinflammatory activation of brain microglia in HG4-treated mice.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: CC BYData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad462&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 1 citations 1 popularity Average influence Average impulse Average Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: CC BYData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad462&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023Publisher:Oxford University Press (OUP) Adeel A Butt; Peng Yan; Obaid S Shaikh; Victor B Talisa; Saad B Omer; Florian B Mayr;pmid: 37711076
Abstract Objective To determine the association of nirmatrelvir/ritonavir (NMV/r) with hospitalization or death within 30 days as compared with untreated controls previously uninfected and nonhospitalized. Methods We used a matched cohort design using inverse probability of treatment weight (IPTW). Individuals prescribed NMV/r within 3 days of COVID-19 diagnosis were compared with IPTW-based untreated controls. Variables for IPTW included age, race, sex, body mass index, geographic location, vaccination status, and multiple comorbidities. Additional analyses were conducted on NMV/r-treated and propensity score–matched untreated controls. Results Among 7615 individuals prescribed NMV/r and 62 077 controls identified between 1 January 2022 and 25 February 2023, the risk of hospitalization/death was lower among NMV/r-treated persons vs untreated controls (243 vs 3468 events; absolute risk difference [ARD], −2.36 [95% CI, −2.57 to −2.14]). The difference was significant for those >60 and ≤60 years old (ARD, −3.86 [95% CI, −4.19 to −3.54] vs −0.27 [95% CI, −0.51 to −0.03]) and for persons asymptomatic and symptomatic (ARD, −7.09 [95% CI, −7.62 to −6.55] vs −1.46 [95% CI, −1.66 to −1.25]). Significant benefit was observed among individuals unvaccinated and vaccinated, with or without a booster dose. Conclusions NMV/r is associated with a significant reduction in 30-day hospitalization or death among individuals previously uninfected and nonhospitalized.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad393&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 1 citations 1 popularity Average influence Average impulse Average Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad393&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023 PortugalPublisher:Oxford University Press (OUP) Funded by:EC | SIMICAEC| SIMICARebelo, Maria; Tang, Cong; Coelho, Ana R; Labão-Almeida, Carlos; Schneider, Matthias M.; Tatalick, Laurie; Ruivo, Pedro; Pires de Miranda, Marta; Gomes, Andreia; Carvalho, Tânia; Walker, Matthew J.; Ausserwoeger, Hannes; Simas, J Pedro; Veldhoen, Marc; Knowles, Tuomas P. J.; Silva, Daniel-Adriano; Shoultz, David; Bernardes, Gonçalo J. L.;The emergence of novel variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need to investigate alternative approaches to prevent infection and treat patients with coronavirus disease 2019. Here, we report the preclinical efficacy of NL-CVX1, a de novo decoy that blocks virus entry into cells by binding with nanomolar affinity and high specificity to the receptor-binding domain of the SARS-CoV-2 spike protein. Using a transgenic mouse model of SARS-CoV-2 infection, we showed that a single prophylactic intranasal dose of NL-CVX1 conferred complete protection from severe disease following SARS-CoV-2 infection. Multiple therapeutic administrations of NL-CVX1 also protected mice from succumbing to infection. Finally, we showed that infected mice treated with NL-CVX1 developed both anti-SARS-CoV-2 antibodies and memory T cells and were protected against reinfection a month after treatment. Overall, these observations suggest NL-CVX1 is a promising therapeutic candidate for preventing and treating severe SARS-CoV-2 infections. © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreements number 852985.
The Journal of Infec... arrow_drop_down Universidade de Lisboa: Repositório.ULArticle . 2023License: CC BYData sources: Universidade de Lisboa: Repositório.ULadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad135&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen hybrid 0 citations 0 popularity Average influence Average impulse Average Powered by BIP!visibility 9visibility views 9 download downloads 1 Powered bymore_vert The Journal of Infec... arrow_drop_down Universidade de Lisboa: Repositório.ULArticle . 2023License: CC BYData sources: Universidade de Lisboa: Repositório.ULadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad135&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023Publisher:Oxford University Press (OUP) Funded by:NIH | A precision medicine fram...NIH| A precision medicine framework to improve long-term outcomes in Sepsis SurvivorsAdeel A Butt; Peng Yan; Obaid S Shaikh; Saad B Omer; Florian B Mayr; Victor B Talisa;Abstract Background Clinical benefit of molnupiravir (MPV) in coronavirus disease 2019 (COVID-19)–infected subpopulations is unclear. Methods We used a matched cohort study design to determine the rate of hospitalization or death within 30 days of COVID-19 diagnosis among MPV treated and untreated controls. Participants were nonhospitalized, previously uninfected Veterans with a first confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between 1 January and 31 August 2022, who were prescribed MPV within 3 days of COVID-19 diagnosis, and matched individuals who were not prescribed MPV. Results Among 1459 matched pairs, the incidence of hospitalization/death was not different among MPV treated versus untreated controls (48 vs 44 cases; absolute risk difference [ARD], 0.27; 95% confidence interval [CI], −.94 to 1.49). No benefit was observed among those >60 or ≤60 years old (ARD, 0.27; 95% CI, −1.25 to 1.79 vs ARD, −0.29; 95% CI, −1.22 to 1.80), those with specific comorbidities, or by vaccination status. A significant benefit was observed in asymptomatic but not in symptomatic persons (ARD, −2.80; 95% CI, −4.74 to −.87 vs ARD, 1.12; 95% CI −.31 to 2.55). Kaplan-Meier curves did not show a difference in proportion of persons who were hospitalized or died among MPV treated compared with untreated controls (logrank P = .7). Conclusions MPV was not associated with a reduction in hospitalization or death within 30 days of COVID-19 diagnosis. A subgroup of patients presenting without symptoms experienced a benefit.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad195&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 3 citations 3 popularity Top 10% influence Average impulse Average Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad195&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023Publisher:Oxford University Press (OUP) Funded by:EC | P2MedEC| P2MedAuthors: Pablo Álvarez-Heredia; Irene Reina-Alfonso; Jose Joaquín Domínguez-del-Castillo; Carmen Gutiérrez-González; +6 AuthorsPablo Álvarez-Heredia; Irene Reina-Alfonso; Jose Joaquín Domínguez-del-Castillo; Carmen Gutiérrez-González; Fakhri Hassouneh; Alexander Batista-Duharte; Ana-Belén Pérez; Raquel Tarazona; Rafael Solana; Alejandra Pera;Abstract Cytomegalovirus (CMV) infection is a major driver of accelerated immunosenescence related to CD28null T cell expansion. CMV infection and these proatherogenic T cells have been independently associated with cardiovascular disease and coronavirus disease 2019 (COVID-19) severity. We investigated the potential contribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to immunosenescence and its relationship with CMV. Innate and adaptive immune subpopulations from individuals with mild or asymptomatic SARS-CoV-2 infection (mCOVID-19) and healthy donors were immunophenotyped. A significant increase in CD28nullCD57+CX3CR1+ T cell percentages (CD4+ [P ≤ .01], CD8+ [P ≤ .01], and TcRγδ (CD4−CD8−) [P ≤ .001]) was found in unnvaccinated CMV-seropositive mCOVID-19 individuals stable up to 12 months after infection. This expansion did not occur in CMV-seronegative mCOVID-19 individuals or in CMV-seropositive individuals infected after SARS-CoV-2 vaccination. There were no significant differences between mCOVID-19 and aortic stenosis groups. Thus, individuals coinfected with SARS-CoV-2 and CMV have accelerated T cell senescence, which might lead to an increased risk of cardiovascular disease.
The Journal of Infec... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad119&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 2 citations 2 popularity Top 10% influence Average impulse Average Powered by BIP!more_vert The Journal of Infec... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad119&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023 Finland, SwitzerlandPublisher:Oxford University Press (OUP) Funded by:EC | SUPPORT-EEC| SUPPORT-ENurmi, Visa; Knight, Chanice; Estcourt, Lise; Hepojoki, Jussi; Lamikanra, Abigail A; Tsang, Hoi P; Roberts, David J; Polack, Fernando P; Simmonds, Peter; Hedman, Klaus; Alvarez-Paggi, Damian; Harvala, Heli;Convalescent plasma (CP) treatment of coronavirus disease 2019 (COVID-19) has shown significant therapeutic effect when administered early (eg, Argentinian trial showing reduced hospitalization) but has in general been ineffective (eg, REMAP-CAP trial without improvement during hospitalization). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralizing antibodies, anti-spike IgG, and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas, emphasizing initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee CP showed significantly higher titers and avidity, being preferable for future CP treatment.Outcomes of 2 clinical SARS-CoV-2 convalescent plasma treatment trials, one effective the other ineffective, were not explained by serological markers of the convalescent plasma used. Start of treatment in relation to disease progression was likely the key factor that determined success. Peer reviewed
Zurich Open Reposito... arrow_drop_down HELDA - Digital Repository of the University of HelsinkiArticle . 2023 . Peer-reviewedData sources: HELDA - Digital Repository of the University of HelsinkiThe Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: CC BYData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad070&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 1 citations 1 popularity Average influence Average impulse Average Powered by BIP!more_vert Zurich Open Reposito... arrow_drop_down HELDA - Digital Repository of the University of HelsinkiArticle . 2023 . Peer-reviewedData sources: HELDA - Digital Repository of the University of HelsinkiThe Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: CC BYData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad070&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2022Publisher:Oxford University Press (OUP) Yu Nakagama; Katherine Candray; Natsuko Kaku; Yuko Komase; Maria-Virginia Rodriguez-Funes; Rhina Dominguez; Tomoya Tsuchida; Hiroyuki Kunishima; Etsuko Nagai; Eisuke Adachi; Dieudonné Mumba Ngoyi; Mari Yamasue; Kosaku Komiya; Kazufumi Hiramatsu; Naoto Uemura; Yuki Sugiura; Mayo Yasugi; Yuka Yamagishi; Hiroshige Mikamo; Satoshi Shiraishi; Takehiro Izumo; Sachie Nakagama; Chihiro Watanabe; Yuko Nitahara; Evariste Tshibangu-Kabamba; Hiroshi Kakeya; Yasutoshi Kido;AbstractBackgroundCross-neutralizing capacity of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is important in mitigating (re-)exposures. Role of antibody maturation, the process whereby selection of higher affinity antibodies augments host immunity, to determine SARS-CoV-2 neutralizing capacity was investigated.MethodsSera from SARS-CoV-2 convalescents at 2, 6, or 10 months postrecovery, and BNT162b2 vaccine recipients at 3 or 25 weeks postvaccination, were analyzed. Anti-spike IgG avidity was measured in urea-treated ELISAs. Neutralizing capacity was assessed by surrogate neutralization assays. Fold change between variant and wild-type neutralization inferred the breadth of neutralizing capacity.ResultsCompared with early-convalescent, avidity indices of late-convalescent sera were significantly higher (median, 37.7 [interquartile range 28.4–45.1] vs 64.9 [57.5–71.5], P < .0001). Urea-resistant, high-avidity IgG best predicted neutralizing capacity (Spearman r = 0.49 vs 0.67 [wild-type]; 0.18–0.52 vs 0.48–0.83 [variants]). Higher-avidity convalescent sera better cross-neutralized SARS-CoV-2 variants (P < .001 [Alpha]; P < .01 [Delta and Omicron]). Vaccinees only experienced meaningful avidity maturation following the booster dose, exhibiting rather limited cross-neutralizing capacity at week 25.ConclusionsAvidity maturation was progressive beyond acute recovery from infection, or became apparent after the booster vaccine dose, granting broader anti-SARS-CoV-2 neutralizing capacity. Understanding the maturation kinetics of the 2 building blocks of anti-SARS-CoV-2 humoral immunity is crucial.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: CC BY NC NDData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac492&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 9 citations 9 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: CC BY NC NDData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac492&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2022Publisher:Oxford University Press (OUP) Funded by:EC | RBDCOVEC| RBDCOVSusana Benet; Oscar Blanch-Lombarte; Erola Ainsua-Enrich; Núria Pedreño-Lopez; Jordana Muñoz-Basagoiti; Dàlia Raïch-Regué; Daniel Perez-Zsolt; Ruth Peña; Esther Jiménez; María Luisa Rodríguez de la Concepción; Carlos Ávila; Samandhy Cedeño; Tuixent Escribà; Luis Romero-Martín; Yovaninna Alarcón-Soto; Gabriel Felipe Rodriguez-Lozano; Cristina Miranda; Sandra González; Lucía Bailón; Julià Blanco; Marta Massanella; Christian Brander; Bonaventura Clotet; Roger Paredes; María Esteve; Nuria Izquierdo-Useros; Jorge Carrillo; Julia G Prado; José Moltó; Beatriz Mothe;Abstract Background We analyzed humoral and cellular immune responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in people with human immunodeficiency virus (HIV; PWH) who had CD4+ T-cell counts <200/µL (HIV<200 group). Methods This prospective cohort study included 58 PWH in the HIV<200 group, 36 with CD4+ T-cell counts >500/µL (HIV>500 group), and 33 HIV-1–negative controls (control group). Antibodies against the SARS-CoV-2 spike protein (anti-S immunoglobulin [Ig] G) and the receptor-binding domain (anti-RBD IgG) were quantified before and 4 weeks after the first and the second doses of BNT162b2 or mRNA-1273 (at week 8). Viral neutralization activity and T-cell responses were also determined. Results At week 8, anti-S/anti-RBD IgG responses increased in all groups (P < .001). Median (interquartile range) anti-S and anti-RBD IgG levels at week 8 were 153.6 (26.4–654.9) and 171.9 (61.8–425.8) binding antibody units (BAU)/mL, respectively, in the HIV<200 group, compared with 245.6 (145–824) and 555.8 (166.4–1751) BAU/mL in the HIV>500 group and 274.7 (193.7–680.4) and 281.6 (181–831.8) BAU/mL in controls (P < .05). Neutralizing capacity and specific T-cell immune responses were absent or reduced in 33% of those in the HIV<200 group, compared with 3.7% in the HIV>500 group (P < .01). Conclusions One-third of PWH with CD4+ T-cell counts <200/µL show low anti-S/anti-RBD IgG levels, reduced in vitro neutralization activity against SARS-CoV-2, and no vaccine-induced T cells after receiving coronavirus disease 2019 mRNA vaccines.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: CrossrefRecolector de Ciencia Abierta, RECOLECTAArticle . 2022Data sources: Recolector de Ciencia Abierta, RECOLECTAadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac406&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 19 citations 19 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: CrossrefRecolector de Ciencia Abierta, RECOLECTAArticle . 2022Data sources: Recolector de Ciencia Abierta, RECOLECTAadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac406&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2022Publisher:Oxford University Press (OUP) Funded by:EC | I-MOVE-COVID-19EC| I-MOVE-COVID-19Authors: Camino Trobajo-Sanmartín; Ana Miqueleiz; Marcela Guevara; Miguel Fernández-Huerta; +6 AuthorsCamino Trobajo-Sanmartín; Ana Miqueleiz; Marcela Guevara; Miguel Fernández-Huerta; Cristina Burgui; Itziar Casado; Fernando Baigorria; Ana Navascués; Carmen Ezpeleta; Jesús Castilla;pmid: 36179126
Abstract Background We compare the risk of coronavirus disease 2019 (COVID-19) outcomes among co-circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants between January 2021 and May 2022 in Navarra, Spain. Methods We compared the frequency of hospitalization and severe disease (intensive care unit admission or death) due to COVID-19 among the co-circulating variants. Variants analyzed were non–variants of concern (non-VOCs), Alpha, Delta, Omicron BA.1, and Omicron BA.2. Logistic regression models were used to estimate adjusted odds ratio (aOR). Results The Alpha variant had a higher risk of hospitalization (aOR, 1.86 [95% confidence interval {CI}, 1.28–2.71]) and severe disease (aOR, 2.40 [95% CI, 1.31–4.40]) than non-VOCs. The Delta variant did not show a significantly different risk of hospitalization (aOR, 0.73 [95% CI, .40–1.30]) and severe disease (aOR, 3.04 [95% CI, .57–16.22]) compared to the Alpha variant. The Omicron BA.1 significantly reduced both risks relative to the Delta variant (aORs, 0.28 [95% CI, .16–.47] and 0.23 [95% CI, .12–.46], respectively). The Omicron BA.2 reduced the risk of hospitalization compared to BA.1 (aOR, 0.52 [95% CI, .29–.95]). Conclusions The Alpha and Delta variants showed an increased risk of hospitalization and severe disease, which decreased considerably with the Omicron BA.1 and BA.2. Surveillance of variants can lead to important differences in severity.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac385&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 8 citations 8 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac385&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2022Publisher:Oxford University Press (OUP) Funded by:EC | EVA-GLOBALEC| EVA-GLOBALMaria R, Farcet; Michael, Karbiener; Simone, Knotzer; Julia, Schwaiger; Thomas R, Kreil;Abstract After >2 years of the coronavirus disease 2019 (COVID-19) pandemic, immunoglobulins (IGs) contain highly potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, based on the large proportion of United States (US) plasma donors who have gone through COVID-19 or vaccination against the virus. Neutralization of Omicron SARS-CoV-2 by antibodies generated after non-Omicron infection or vaccination has been lower though, raising concerns about the potency of IG against this new virus variant. Also, as plasma collected in the US remains the main source of IG, the neutralization of SARS-CoV-2 for plasma collected elsewhere has been less well studied. Here, we confirm Omicron neutralization by US as well as European Union plasma–derived IG lots.
The Journal of Infec... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac358&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 7 citations 7 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert The Journal of Infec... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac358&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu
Loading
description Publicationkeyboard_double_arrow_right Article 2023Publisher:Oxford University Press (OUP) Funded by:EC | ERVEEC| ERVEYoussif M Ali; George W Carnell; Stefano Fumagalli; Domenico Mercurio; Serena Seminara; Nicholas J Lynch; Priyanka Khatri; Chanuka H Arachchilage; Luca Mascheroni; Clemens Kaminski; Charlotte L George; Hazel Stewart; Munehisa Yabuki; Gregory Demopulos; Jonathan L Heeney; Wilhelm Schwaeble;pmid: 37878754
Abstract Most patients with COVID-19 in the intensive care unit develop an acute respiratory distress syndrome characterized by severe hypoxemia, decreased lung compliance, and high vascular permeability. Activation of the complement system is a hallmark of moderate and severe COVID-19, with abundant deposition of complement proteins in inflamed tissue and on the endothelium during COVID-19. Using a transgenic mouse model of SARS-CoV-2 infection, we assessed the therapeutic utility of an inhibitory antibody (HG4) targeting MASP-2, a key enzyme in the lectin pathway. Treatment of infected mice with HG4 reduced the disease severity score and improved survival vs mice that received an isotype control antibody. Administration of HG4 significantly reduced the lung injury score, including alveolar inflammatory cell infiltration, alveolar edema, and alveolar hemorrhage. The ameliorating effect of MASP-2 inhibition on the severity of COVID-19 pathology is reflected by a significant reduction in the proinflammatory activation of brain microglia in HG4-treated mice.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: CC BYData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad462&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 1 citations 1 popularity Average influence Average impulse Average Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: CC BYData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad462&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023Publisher:Oxford University Press (OUP) Adeel A Butt; Peng Yan; Obaid S Shaikh; Victor B Talisa; Saad B Omer; Florian B Mayr;pmid: 37711076
Abstract Objective To determine the association of nirmatrelvir/ritonavir (NMV/r) with hospitalization or death within 30 days as compared with untreated controls previously uninfected and nonhospitalized. Methods We used a matched cohort design using inverse probability of treatment weight (IPTW). Individuals prescribed NMV/r within 3 days of COVID-19 diagnosis were compared with IPTW-based untreated controls. Variables for IPTW included age, race, sex, body mass index, geographic location, vaccination status, and multiple comorbidities. Additional analyses were conducted on NMV/r-treated and propensity score–matched untreated controls. Results Among 7615 individuals prescribed NMV/r and 62 077 controls identified between 1 January 2022 and 25 February 2023, the risk of hospitalization/death was lower among NMV/r-treated persons vs untreated controls (243 vs 3468 events; absolute risk difference [ARD], −2.36 [95% CI, −2.57 to −2.14]). The difference was significant for those >60 and ≤60 years old (ARD, −3.86 [95% CI, −4.19 to −3.54] vs −0.27 [95% CI, −0.51 to −0.03]) and for persons asymptomatic and symptomatic (ARD, −7.09 [95% CI, −7.62 to −6.55] vs −1.46 [95% CI, −1.66 to −1.25]). Significant benefit was observed among individuals unvaccinated and vaccinated, with or without a booster dose. Conclusions NMV/r is associated with a significant reduction in 30-day hospitalization or death among individuals previously uninfected and nonhospitalized.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad393&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 1 citations 1 popularity Average influence Average impulse Average Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad393&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023 PortugalPublisher:Oxford University Press (OUP) Funded by:EC | SIMICAEC| SIMICARebelo, Maria; Tang, Cong; Coelho, Ana R; Labão-Almeida, Carlos; Schneider, Matthias M.; Tatalick, Laurie; Ruivo, Pedro; Pires de Miranda, Marta; Gomes, Andreia; Carvalho, Tânia; Walker, Matthew J.; Ausserwoeger, Hannes; Simas, J Pedro; Veldhoen, Marc; Knowles, Tuomas P. J.; Silva, Daniel-Adriano; Shoultz, David; Bernardes, Gonçalo J. L.;The emergence of novel variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need to investigate alternative approaches to prevent infection and treat patients with coronavirus disease 2019. Here, we report the preclinical efficacy of NL-CVX1, a de novo decoy that blocks virus entry into cells by binding with nanomolar affinity and high specificity to the receptor-binding domain of the SARS-CoV-2 spike protein. Using a transgenic mouse model of SARS-CoV-2 infection, we showed that a single prophylactic intranasal dose of NL-CVX1 conferred complete protection from severe disease following SARS-CoV-2 infection. Multiple therapeutic administrations of NL-CVX1 also protected mice from succumbing to infection. Finally, we showed that infected mice treated with NL-CVX1 developed both anti-SARS-CoV-2 antibodies and memory T cells and were protected against reinfection a month after treatment. Overall, these observations suggest NL-CVX1 is a promising therapeutic candidate for preventing and treating severe SARS-CoV-2 infections. © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreements number 852985.
The Journal of Infec... arrow_drop_down Universidade de Lisboa: Repositório.ULArticle . 2023License: CC BYData sources: Universidade de Lisboa: Repositório.ULadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad135&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen hybrid 0 citations 0 popularity Average influence Average impulse Average Powered by BIP!visibility 9visibility views 9 download downloads 1 Powered bymore_vert The Journal of Infec... arrow_drop_down Universidade de Lisboa: Repositório.ULArticle . 2023License: CC BYData sources: Universidade de Lisboa: Repositório.ULadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad135&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023Publisher:Oxford University Press (OUP) Funded by:NIH | A precision medicine fram...NIH| A precision medicine framework to improve long-term outcomes in Sepsis SurvivorsAdeel A Butt; Peng Yan; Obaid S Shaikh; Saad B Omer; Florian B Mayr; Victor B Talisa;Abstract Background Clinical benefit of molnupiravir (MPV) in coronavirus disease 2019 (COVID-19)–infected subpopulations is unclear. Methods We used a matched cohort study design to determine the rate of hospitalization or death within 30 days of COVID-19 diagnosis among MPV treated and untreated controls. Participants were nonhospitalized, previously uninfected Veterans with a first confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between 1 January and 31 August 2022, who were prescribed MPV within 3 days of COVID-19 diagnosis, and matched individuals who were not prescribed MPV. Results Among 1459 matched pairs, the incidence of hospitalization/death was not different among MPV treated versus untreated controls (48 vs 44 cases; absolute risk difference [ARD], 0.27; 95% confidence interval [CI], −.94 to 1.49). No benefit was observed among those >60 or ≤60 years old (ARD, 0.27; 95% CI, −1.25 to 1.79 vs ARD, −0.29; 95% CI, −1.22 to 1.80), those with specific comorbidities, or by vaccination status. A significant benefit was observed in asymptomatic but not in symptomatic persons (ARD, −2.80; 95% CI, −4.74 to −.87 vs ARD, 1.12; 95% CI −.31 to 2.55). Kaplan-Meier curves did not show a difference in proportion of persons who were hospitalized or died among MPV treated compared with untreated controls (logrank P = .7). Conclusions MPV was not associated with a reduction in hospitalization or death within 30 days of COVID-19 diagnosis. A subgroup of patients presenting without symptoms experienced a benefit.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad195&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 3 citations 3 popularity Top 10% influence Average impulse Average Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad195&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023Publisher:Oxford University Press (OUP) Funded by:EC | P2MedEC| P2MedAuthors: Pablo Álvarez-Heredia; Irene Reina-Alfonso; Jose Joaquín Domínguez-del-Castillo; Carmen Gutiérrez-González; +6 AuthorsPablo Álvarez-Heredia; Irene Reina-Alfonso; Jose Joaquín Domínguez-del-Castillo; Carmen Gutiérrez-González; Fakhri Hassouneh; Alexander Batista-Duharte; Ana-Belén Pérez; Raquel Tarazona; Rafael Solana; Alejandra Pera;Abstract Cytomegalovirus (CMV) infection is a major driver of accelerated immunosenescence related to CD28null T cell expansion. CMV infection and these proatherogenic T cells have been independently associated with cardiovascular disease and coronavirus disease 2019 (COVID-19) severity. We investigated the potential contribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to immunosenescence and its relationship with CMV. Innate and adaptive immune subpopulations from individuals with mild or asymptomatic SARS-CoV-2 infection (mCOVID-19) and healthy donors were immunophenotyped. A significant increase in CD28nullCD57+CX3CR1+ T cell percentages (CD4+ [P ≤ .01], CD8+ [P ≤ .01], and TcRγδ (CD4−CD8−) [P ≤ .001]) was found in unnvaccinated CMV-seropositive mCOVID-19 individuals stable up to 12 months after infection. This expansion did not occur in CMV-seronegative mCOVID-19 individuals or in CMV-seropositive individuals infected after SARS-CoV-2 vaccination. There were no significant differences between mCOVID-19 and aortic stenosis groups. Thus, individuals coinfected with SARS-CoV-2 and CMV have accelerated T cell senescence, which might lead to an increased risk of cardiovascular disease.
The Journal of Infec... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad119&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 2 citations 2 popularity Top 10% influence Average impulse Average Powered by BIP!more_vert The Journal of Infec... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad119&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2023 Finland, SwitzerlandPublisher:Oxford University Press (OUP) Funded by:EC | SUPPORT-EEC| SUPPORT-ENurmi, Visa; Knight, Chanice; Estcourt, Lise; Hepojoki, Jussi; Lamikanra, Abigail A; Tsang, Hoi P; Roberts, David J; Polack, Fernando P; Simmonds, Peter; Hedman, Klaus; Alvarez-Paggi, Damian; Harvala, Heli;Convalescent plasma (CP) treatment of coronavirus disease 2019 (COVID-19) has shown significant therapeutic effect when administered early (eg, Argentinian trial showing reduced hospitalization) but has in general been ineffective (eg, REMAP-CAP trial without improvement during hospitalization). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralizing antibodies, anti-spike IgG, and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas, emphasizing initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee CP showed significantly higher titers and avidity, being preferable for future CP treatment.Outcomes of 2 clinical SARS-CoV-2 convalescent plasma treatment trials, one effective the other ineffective, were not explained by serological markers of the convalescent plasma used. Start of treatment in relation to disease progression was likely the key factor that determined success. Peer reviewed
Zurich Open Reposito... arrow_drop_down HELDA - Digital Repository of the University of HelsinkiArticle . 2023 . Peer-reviewedData sources: HELDA - Digital Repository of the University of HelsinkiThe Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: CC BYData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad070&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 1 citations 1 popularity Average influence Average impulse Average Powered by BIP!more_vert Zurich Open Reposito... arrow_drop_down HELDA - Digital Repository of the University of HelsinkiArticle . 2023 . Peer-reviewedData sources: HELDA - Digital Repository of the University of HelsinkiThe Journal of Infectious DiseasesArticle . 2023 . Peer-reviewedLicense: CC BYData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiad070&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2022Publisher:Oxford University Press (OUP) Yu Nakagama; Katherine Candray; Natsuko Kaku; Yuko Komase; Maria-Virginia Rodriguez-Funes; Rhina Dominguez; Tomoya Tsuchida; Hiroyuki Kunishima; Etsuko Nagai; Eisuke Adachi; Dieudonné Mumba Ngoyi; Mari Yamasue; Kosaku Komiya; Kazufumi Hiramatsu; Naoto Uemura; Yuki Sugiura; Mayo Yasugi; Yuka Yamagishi; Hiroshige Mikamo; Satoshi Shiraishi; Takehiro Izumo; Sachie Nakagama; Chihiro Watanabe; Yuko Nitahara; Evariste Tshibangu-Kabamba; Hiroshi Kakeya; Yasutoshi Kido;AbstractBackgroundCross-neutralizing capacity of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is important in mitigating (re-)exposures. Role of antibody maturation, the process whereby selection of higher affinity antibodies augments host immunity, to determine SARS-CoV-2 neutralizing capacity was investigated.MethodsSera from SARS-CoV-2 convalescents at 2, 6, or 10 months postrecovery, and BNT162b2 vaccine recipients at 3 or 25 weeks postvaccination, were analyzed. Anti-spike IgG avidity was measured in urea-treated ELISAs. Neutralizing capacity was assessed by surrogate neutralization assays. Fold change between variant and wild-type neutralization inferred the breadth of neutralizing capacity.ResultsCompared with early-convalescent, avidity indices of late-convalescent sera were significantly higher (median, 37.7 [interquartile range 28.4–45.1] vs 64.9 [57.5–71.5], P < .0001). Urea-resistant, high-avidity IgG best predicted neutralizing capacity (Spearman r = 0.49 vs 0.67 [wild-type]; 0.18–0.52 vs 0.48–0.83 [variants]). Higher-avidity convalescent sera better cross-neutralized SARS-CoV-2 variants (P < .001 [Alpha]; P < .01 [Delta and Omicron]). Vaccinees only experienced meaningful avidity maturation following the booster dose, exhibiting rather limited cross-neutralizing capacity at week 25.ConclusionsAvidity maturation was progressive beyond acute recovery from infection, or became apparent after the booster vaccine dose, granting broader anti-SARS-CoV-2 neutralizing capacity. Understanding the maturation kinetics of the 2 building blocks of anti-SARS-CoV-2 humoral immunity is crucial.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: CC BY NC NDData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac492&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 9 citations 9 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: CC BY NC NDData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac492&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2022Publisher:Oxford University Press (OUP) Funded by:EC | RBDCOVEC| RBDCOVSusana Benet; Oscar Blanch-Lombarte; Erola Ainsua-Enrich; Núria Pedreño-Lopez; Jordana Muñoz-Basagoiti; Dàlia Raïch-Regué; Daniel Perez-Zsolt; Ruth Peña; Esther Jiménez; María Luisa Rodríguez de la Concepción; Carlos Ávila; Samandhy Cedeño; Tuixent Escribà; Luis Romero-Martín; Yovaninna Alarcón-Soto; Gabriel Felipe Rodriguez-Lozano; Cristina Miranda; Sandra González; Lucía Bailón; Julià Blanco; Marta Massanella; Christian Brander; Bonaventura Clotet; Roger Paredes; María Esteve; Nuria Izquierdo-Useros; Jorge Carrillo; Julia G Prado; José Moltó; Beatriz Mothe;Abstract Background We analyzed humoral and cellular immune responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in people with human immunodeficiency virus (HIV; PWH) who had CD4+ T-cell counts <200/µL (HIV<200 group). Methods This prospective cohort study included 58 PWH in the HIV<200 group, 36 with CD4+ T-cell counts >500/µL (HIV>500 group), and 33 HIV-1–negative controls (control group). Antibodies against the SARS-CoV-2 spike protein (anti-S immunoglobulin [Ig] G) and the receptor-binding domain (anti-RBD IgG) were quantified before and 4 weeks after the first and the second doses of BNT162b2 or mRNA-1273 (at week 8). Viral neutralization activity and T-cell responses were also determined. Results At week 8, anti-S/anti-RBD IgG responses increased in all groups (P < .001). Median (interquartile range) anti-S and anti-RBD IgG levels at week 8 were 153.6 (26.4–654.9) and 171.9 (61.8–425.8) binding antibody units (BAU)/mL, respectively, in the HIV<200 group, compared with 245.6 (145–824) and 555.8 (166.4–1751) BAU/mL in the HIV>500 group and 274.7 (193.7–680.4) and 281.6 (181–831.8) BAU/mL in controls (P < .05). Neutralizing capacity and specific T-cell immune responses were absent or reduced in 33% of those in the HIV<200 group, compared with 3.7% in the HIV>500 group (P < .01). Conclusions One-third of PWH with CD4+ T-cell counts <200/µL show low anti-S/anti-RBD IgG levels, reduced in vitro neutralization activity against SARS-CoV-2, and no vaccine-induced T cells after receiving coronavirus disease 2019 mRNA vaccines.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: CrossrefRecolector de Ciencia Abierta, RECOLECTAArticle . 2022Data sources: Recolector de Ciencia Abierta, RECOLECTAadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac406&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 19 citations 19 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: CrossrefRecolector de Ciencia Abierta, RECOLECTAArticle . 2022Data sources: Recolector de Ciencia Abierta, RECOLECTAadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac406&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2022Publisher:Oxford University Press (OUP) Funded by:EC | I-MOVE-COVID-19EC| I-MOVE-COVID-19Authors: Camino Trobajo-Sanmartín; Ana Miqueleiz; Marcela Guevara; Miguel Fernández-Huerta; +6 AuthorsCamino Trobajo-Sanmartín; Ana Miqueleiz; Marcela Guevara; Miguel Fernández-Huerta; Cristina Burgui; Itziar Casado; Fernando Baigorria; Ana Navascués; Carmen Ezpeleta; Jesús Castilla;pmid: 36179126
Abstract Background We compare the risk of coronavirus disease 2019 (COVID-19) outcomes among co-circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants between January 2021 and May 2022 in Navarra, Spain. Methods We compared the frequency of hospitalization and severe disease (intensive care unit admission or death) due to COVID-19 among the co-circulating variants. Variants analyzed were non–variants of concern (non-VOCs), Alpha, Delta, Omicron BA.1, and Omicron BA.2. Logistic regression models were used to estimate adjusted odds ratio (aOR). Results The Alpha variant had a higher risk of hospitalization (aOR, 1.86 [95% confidence interval {CI}, 1.28–2.71]) and severe disease (aOR, 2.40 [95% CI, 1.31–4.40]) than non-VOCs. The Delta variant did not show a significantly different risk of hospitalization (aOR, 0.73 [95% CI, .40–1.30]) and severe disease (aOR, 3.04 [95% CI, .57–16.22]) compared to the Alpha variant. The Omicron BA.1 significantly reduced both risks relative to the Delta variant (aORs, 0.28 [95% CI, .16–.47] and 0.23 [95% CI, .12–.46], respectively). The Omicron BA.2 reduced the risk of hospitalization compared to BA.1 (aOR, 0.52 [95% CI, .29–.95]). Conclusions The Alpha and Delta variants showed an increased risk of hospitalization and severe disease, which decreased considerably with the Omicron BA.1 and BA.2. Surveillance of variants can lead to important differences in severity.
The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac385&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routesbronze 8 citations 8 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert The Journal of Infec... arrow_drop_down The Journal of Infectious DiseasesArticle . 2022 . Peer-reviewedLicense: OUP Standard Publication ReuseData sources: Crossrefadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac385&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2022Publisher:Oxford University Press (OUP) Funded by:EC | EVA-GLOBALEC| EVA-GLOBALMaria R, Farcet; Michael, Karbiener; Simone, Knotzer; Julia, Schwaiger; Thomas R, Kreil;Abstract After >2 years of the coronavirus disease 2019 (COVID-19) pandemic, immunoglobulins (IGs) contain highly potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, based on the large proportion of United States (US) plasma donors who have gone through COVID-19 or vaccination against the virus. Neutralization of Omicron SARS-CoV-2 by antibodies generated after non-Omicron infection or vaccination has been lower though, raising concerns about the potency of IG against this new virus variant. Also, as plasma collected in the US remains the main source of IG, the neutralization of SARS-CoV-2 for plasma collected elsewhere has been less well studied. Here, we confirm Omicron neutralization by US as well as European Union plasma–derived IG lots.
The Journal of Infec... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac358&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess Routeshybrid 7 citations 7 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert The Journal of Infec... arrow_drop_down add ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1093/infdis/jiac358&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu